CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 118 enrolled
Drug / intervention
Enlite 3 +2 moredevice
Likely dose
640G Insulin Pumpfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02246582
NCT02246582N/ACompleted
CompareCT.gov

A Performance Evaluation of the Enlite® 3 Sensor to Support a Full 168 Hours (7 Days) of Use

Medtronic MiniMed, Inc.·interventional·Posted Sep 23, 2014·Updated Nov 2, 2016

In Brief

A clinical study evaluating Enlite 3, Guardian Mobile App, and 1 other intervention for Type 1 Diabetes and Type 2 Diabetes. Completed, enrolled 118 participants across 6 sites.

Detailed Summary

The purpose of this study is to demonstrate the performance of the Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen and used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years with type 1 or type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes, Type 2 Diabetes
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 23, 2014
Enrollment StartSep 1, 2014
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.8 years ago

Interventions

Enlite 3device

Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen \& arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.

Guardian Mobile Appdevice

640G Insulin Pumpdevice